Teleflex Incorporated (NYSE:TFX) shares reached a new 52-week high on Wednesday . The company traded as high as $301.93 and last traded at $299.86, with a volume of 4956 shares changing hands. The stock had previously closed at $296.44.
A number of research analysts have recently weighed in on TFX shares. Morgan Stanley raised their price target on shares of Teleflex from $295.00 to $305.00 and gave the company an “overweight” rating in a report on Wednesday, January 2nd. Barclays set a $287.00 price target on shares of Teleflex and gave the company a “hold” rating in a report on Friday, February 22nd. UBS Group started coverage on shares of Teleflex in a report on Tuesday, November 27th. They set a “buy” rating and a $310.00 price target on the stock. TheStreet upgraded shares of Teleflex from a “c+” rating to a “b-” rating in a report on Wednesday, November 28th. Finally, Zacks Investment Research upgraded shares of Teleflex from a “sell” rating to a “hold” rating in a report on Tuesday, February 26th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Teleflex currently has an average rating of “Buy” and a consensus target price of $297.00.
The firm has a market capitalization of $13.64 billion, a P/E ratio of 30.19, a price-to-earnings-growth ratio of 1.99 and a beta of 1.06. The company has a current ratio of 2.12, a quick ratio of 1.39 and a debt-to-equity ratio of 0.82.
Teleflex (NYSE:TFX) last announced its earnings results on Thursday, February 21st. The medical technology company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.76 by $0.01. The firm had revenue of $641.60 million for the quarter, compared to the consensus estimate of $641.06 million. Teleflex had a net margin of 8.20% and a return on equity of 18.47%. The business’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the firm posted $2.44 EPS. As a group, equities analysts expect that Teleflex Incorporated will post 11.02 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, March 15th. Investors of record on Friday, March 1st will be issued a $0.34 dividend. The ex-dividend date is Thursday, February 28th. This represents a $1.36 annualized dividend and a yield of 0.46%. Teleflex’s dividend payout ratio (DPR) is presently 13.74%.
In other news, Director John C. Heinmiller bought 1,250 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The shares were purchased at an average price of $285.00 per share, for a total transaction of $356,250.00. Following the acquisition, the director now directly owns 634 shares of the company’s stock, valued at approximately $180,690. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Thomas E. Powell sold 5,324 shares of Teleflex stock in a transaction on Thursday, December 27th. The stock was sold at an average price of $242.25, for a total transaction of $1,289,739.00. Following the completion of the transaction, the chief financial officer now owns 13,775 shares in the company, valued at approximately $3,336,993.75. The disclosure for this sale can be found here. Insiders sold a total of 21,924 shares of company stock worth $5,828,431 in the last quarter. Insiders own 2.56% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Exane Derivatives acquired a new stake in Teleflex in the 4th quarter worth $41,000. Bronfman E.L. Rothschild L.P. grew its position in Teleflex by 17.7% in the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 239 shares of the medical technology company’s stock worth $62,000 after purchasing an additional 36 shares during the last quarter. Valeo Financial Advisors LLC grew its position in Teleflex by 42.2% in the 4th quarter. Valeo Financial Advisors LLC now owns 337 shares of the medical technology company’s stock worth $87,000 after purchasing an additional 100 shares during the last quarter. Simplex Trading LLC grew its position in Teleflex by 6,466.7% in the 4th quarter. Simplex Trading LLC now owns 394 shares of the medical technology company’s stock worth $101,000 after purchasing an additional 388 shares during the last quarter. Finally, Bremer Trust National Association acquired a new stake in Teleflex in the 4th quarter worth $116,000. Institutional investors own 91.17% of the company’s stock.
Teleflex Company Profile (NYSE:TFX)
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
Read More: Technical Analysis
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.